Competent Cells Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

The competent cells market is expected to register a CAGR of 9.4% over the forecast period.

The COVID-19 pandemic had a significant effect on the competent cells market. The increasing usage of competent cells in the research and development activities for the cell cloning activities of SARS-CoV-2. For example, an article published by Nature Journal in January 2021 reported the construction of a full-length SARS-CoV-2 genome via in-vitro competent cells in order to study the virus in-vitro and in vivo. Such application of competent cells in cloning the virus genome in order to develop appropriate treatments had a significant impact on the growth of the market. In addition, the demand for competent cells is expected to remain intact due to the emergence of a mutant strain of SARS-CoV-2 and to understand their mechanisms as well, thereby contributing to the growth of the market over the forecast period.

Advancements in molecular engineering due to the emergence of new cell technologies in biotechnology industries are augmenting the growth of the market studied. Additionally, increased investments from public and private companies and the development of advanced products are anticipated to boost the market growth in the studied regions. For example, in December 2021, Pfizer announced opening of a new state-of-the-art clinical manufacturing facility in Durham. The facility will expand Pfizer’s end-to-end capabilities in gene therapy and builds on the company’s existing footprint in North Carolina. The Durham facility is part of a USD 800 million investment over the past six years to build three scalable, state-of-the-art gene therapy manufacturing facilities to support Pfizer’s continued investment in gene therapy. Such increasing investment by various market players for the development of various advanced therapies is also expected to drive the demand for competent cells owing to the high efficacy in various biotechnology procedures, thereby contributing to the growth of the market.

According to an SEU article published in July 2022, venture capitalists in Europe invested nearly over USD 18 billion into European biotech startups. Such high amounts of capital-raising capabilities from major companies are likely to lead to further investment in research and development activities. They are also expected to drive the growth of the market over the forecast period.

However, the very high cost of research and development of competent cells and the market consolidation of a few major players are expected to hamper the market growth over the period.

Competent Cells Market Trends

Biotechnology is Expected to Register Good Growth Rate Over the Forecast Period

The biotechnology segment is also projected to witness a notable growth rate due to increasing investments in R&D and the commercialization of proteomics and genomic-based products. Furthermore, the need for advanced product technologies in the treatment of various diseases is projected to bolster the segment's growth. These areas are likely to see renewed interest, due to which demand for competent cells will increase, as they can be used in therapeutic biotechnology research.

In addition, increased funding for studies for biotechnology for the market players and research institutions by various government organizations is also expected to contribute to the growth of the studied segment. For instance, in August 2022, the Minister of Science and Technology announced grants for collaborative biotech initiatives involving India's startups, industry, academic, and research bodies. The participants can avail of grants of INR 10-15 crores (USD 12.08 million) over three years for high-quality research. Similarly, the Biotechnology Ignition Grant Scheme (BIG) was implemented by the Government of India to fund biotech startups with USD 70,000. Such increasing funding for biotechnology is expected to contribute to the demand for competent cells as they are widely used in biotechnology research, thereby fueling segment growth.

North America is Expected to Register Notable Growth in the Market Over the Forecast Period

The North American market is anticipated to hold a majority share of the global competent cells market during the forecast period. The growth is attributed to extensive studies on DNA cloning technologies, increasing biotechnology research, high research and development expenditure in the region, and the presence of key market players.

For example, the article published by NIH in March 2022 mentioned that the funding for biotechnology research in the United States in 2021 was USD 7,847 million and is expected to reach USD 8,104 by 2030. Similarly, the Government of Canada data published in 2022 mentioned that the Government of Canada invested over USD 500 million for four years, starting 2021-2022, to support the bioscience infrastructure in Canada. Such increasing funding activities for the development of various biotechnology research activities involving the vast utilization of competent cells are also expected to contribute to the growth of the market.

Moreover, increasing market players' strategies, such as collaborations, agreements, investments, and others for DNA-based research, is also expected to contribute to the growth of the market. For instance, in May 2022, Avantor agreed with CytovanceBiologics, a contract development and manufacturing organization specializing in plasmid DNA, to manufacture research- and good manufacturing practice (GMP)-grade plasmids for viral vectors and messenger RNA (mRNA)-based vaccines and therapeutics. Also, in January 2022, Alcami, a United States-based pharmaceutical contract development and manufacturing organization (CDMO), is investing USD 10 million to expand its laboratory operation in North Carolina, United States, to enhance its large molecule and cell and gene therapy analytical service offering.

Thus, the rising funding activities for biotechnology research, along with extensive DNA-based studies and market players' strategies, are expected to contribute to the growth of the market in this region.

Competent Cells Market Competitor Analysis

The competent cells market is moderately consolidated with a notable number of market players. Companies are focusing on developing new technologies in cell DNA cloning and broadening the applications of competent cells. The key market players operating in the market include Thermo Fisher Scientific, Merck KGaA, Qiagen, Takara Bio Inc., and New England BioLabs Inc.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.